Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Justin Hunter

Vascular Surgery Memphis, TN Medical Doctor

NPI 1154715134 CMS profile 4221226

1211 Union Ave Ste 300, Memphis, TN 38104

Open in the dashboard

General payments

$8,079

60 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Hunter of Memphis, TN is reported in the CMS Open Payments database as having received $8,079 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $414 4
2024 General $3,632 20
2023 General $1,809 15
2022 General $1,839 15
2021 General $161 3
2020 General $206 2
2019 General $18 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Hunter
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Justin Hunter were reported at $414. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Justin Hunter Vascular Surgery median Middle half National median
2019 $18 $796 $226–$2,363 $163
2020 $206 $348 $118–$1,110 $114
2021 $161 $471 $158–$1,421 $132
2022 $1,839 $725 $222–$2,183 $149
2023 $1,809 $836 $257–$2,440 $160
2024 $3,632 $909 $252–$2,619 $164
2025 $414 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,334 14 payments
  2. W. L. Gore & Associates, Inc. $1,879 14 payments
  3. Penumbra, Inc. $1,637 6 payments
  4. Medtronic, Inc. $789 6 payments
  5. Shockwave Medical, Inc $675 6 payments
  6. Medtronic Vascular, Inc. $191 1 payment
  7. Endologix, Inc. $174 2 payments
  8. AngioDynamics, Inc. $122 2 payments
  9. Silk Road Medical, Inc. $111 1 payment
  10. Boston Scientific Corporation $66 4 payments
  11. Other $101 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $4,413 19 payments
  2. Food and Beverage $3,353 39 payments
  3. Education $312 2 payments
Products named General payments · program years 2019–2025
  1. RUBY Coil $1,637 6 payments
  2. SUPERA $1,312 8 payments
  3. GORE TAG Thoracic Endoprosthesis $1,029 10 payments
  4. OMNILINK ELITE $1,021 6 payments
  5. GORE TAG Thoracic Branch Endoprosthesis $766 3 payments
  6. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $675 6 payments
  7. ENDURANT IIS $513 3 payments
  8. ENDOCROSS Device $174 2 payments
  9. Torus Stent Graft System $174 2 payments
  10. ELLIPSYS VASCULAR ACCESS SYSTEM $148 1 payment
  11. Other $723 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

62

Median for Vascular Surgery: 122

Drug cost

$13,592

Median for Vascular Surgery: $14,135

Branded share of claims

74.2%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 13 $13,047
Cilostazol Generic 16 $286
Clopidogrel Clopidogrel Bisulfate Brand 33 $259

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$36,351

Medicare's payments for the services billed

Medicare patients

170

Average age 72

Services billed

363

71 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 59%
Diabetes 58%
Ischemic heart disease 56%
Heart failure 51%
Arthritis 38%
COPD 31%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record